Evaluation of the in vivo Antifungal Effects of Ankaferd Blood Stopper in a Neutropenic Rat Model of Systemic Candidiasis

Year 2025, Volume: 7 Issue: 3, 109 - 116, 29.07.2025

İnci Yılmaz Nakir , Funda Yetkin , Nurhan Şahin

https://doi.org/10.46310/tjim.1723416

Abstract

Background This study aimed to evaluate the in vivo antifungal effects of Ankaferd Blood Stopper (ABS) in a neutropenic rat model of systemic Candida albicans infection.
Methods A total of 24 Wistar-Albino rats were divided into two groups: one receiving ABS and the other receiving normal saline (control group). Neutropenia was induced using cyclophosphamide, followed by intraperitoneal C. albicans inoculation. The ABS group received 1 mL of ABS via an orogastric tube, while the control group received 1 mL of saline. The rats were monitored for clinical changes, and histopathological evaluations were conducted on liver, lung, and kidney tissues.
Results While no significant antifungal effect was observed in the lung (p=0.590) and kidney tissues (p=1.000), ABS-treated rats showed statistically significant lymphoid infiltration (p=0.014) and hepatocyte regeneration in liver tissue (p=0.001). This suggests that ABS may enhance immune response and promote tissue healing.
Conclusion In this regard, our study is the first and only study to evaluate the in vivo antifungal efficacy of Ankaferd. The findings indicate that ABS may have immunomodulatory effects in systemic candidiasis, particularly in liver tissue. However, further studies are required to elucidate its pharmacokinetics and optimal dosing for antifungal efficacy.

Keywords

Ankaferd Blood Stopper, antifungal effect, Candida albicans, neutropenic model

Ethical Statement

This study was supported by the İnönü University Scientific Research Projects Coordination Unit (IUBAP) under project number 2013/101. The authors have no conflict of interest to declare. Informed consent Ethics committee approval was obtained from the İnönü University Faculty of Medicine Experimental Animals Ethics Committee (Protocol No: 2012/A-116, 27.12.2012).

Supporting Institution

İnönü University Scientific Research Projects Coordination Unit (IUBAP)

Project Number

Protocol No: 2012/A-116, 27.12.2012

Thanks

We sincerely thank the Scientific Research Projects Coordination Unit for their support.

References

• Ciftciler R, Ciftciler AE, Malkan UY, Haznedaroglu IC. Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper). SAGE Open Medicine. 2020;8. doi:10.1177/2050312120907811.
• Çiftçiler R, Haznedaroglu İC. Ankaferd hemostat: from molecules to medicine. Turk J Med Sci. 2020 Nov 3;50(SI-2):1739-1750. doi: 10.3906/sag-1908-161.
• Semiz A. Drug interaction potential of Ankaferd blood stopper® in human hepatocarcinoma cells. Turk J Med Sci. 2023 Apr;53(2):455-462. doi: 10.55730/1300-0144.5605.
• Çiftçiler R, Aksu S, Dikmenoğlu Falkmarken N, Haznedaroğlu İC. Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study. Turk J Med Sci. 2019 Feb 11;49(1):356-360. doi: 10.3906/sag-1808-60.
• Yılmaz AÇ, Aygın D. Evaluation of the effects of three natural products and a hemostatic agent on wound healing: an experimental study. Turk J Med Sci. 2023 Feb;53(1):58-67. doi: 10.55730/1300-0144.5558.
• Xu H, Yang J, Wei Z, Bao S, Liu Z. Oxidative stress in vascular surgical diseases: mechanisms, impacts and therapeutic perspectives. Front Pharmacol. 2025 Apr 9;16:1527684. doi: 10.3389/fphar.2025.1527684.
• Hancioğlu S, Demirel BD, Biçakci Ü, Gün S, Aritürk E, Aritürk N. Histopathological and mechanical effects of Ankaferd Blood Stopper® on wound healing in rats: an experimental model. Turk J Med Sci. 2020 Aug 26;50(5):1428-1433. doi: 10.3906/sag-2004-177.
• Beyazit F, Beyazit Y, Tanoglu A, Haznedaroglu IC. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Med Hypotheses. 2020 Oct;143:110150. doi: 10.1016/j.mehy.2020.110150.
• Lu H, Hong T, Jiang Y, Whiteway M, Zhang S. Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies. Adv Drug Deliv Rev. 2023 Aug;199:114960. doi: 10.1016/j.addr.2023.114960.
• Echeverria-Esnal D, Martín-Ontiyuelo C, Navarrete-Rouco ME, Barcelo-Vidal J, Conde-Estévez D, Carballo N, De-Antonio Cuscó M, Ferrández O, Horcajada JP, Grau S. Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Rev Anti Infect Ther. 2022 Feb;20(2):179-197. doi: 10.1080/14787210.2021.1962292.
• Boran R, Baygar T, Saraç, N, and Uğur A. Ankaferd Blood Stopper with antibiofilm potential successfully inhibits the extracellularmatrix degradation enzymes and promotes wound healing of 3T3 fibroblasts in vitro. Turk J Med Sci (2018) 48: 627-634. doi:10.3906/sag-1712-80.
• Koluman A, Aktaş A, Adiloğlu S. Antimicrobial activities of Ankaferd BloodStopper, hypochlorous acid, and chlorhexidine against specific organisms. Turk J Med Sci. 2022 Feb;52(1):276-278. doi: 10.3906/sag-2107-24.
• Saribas Z, Sener B, Haznedaroglu I, Hascelik G, Kirazli S, Goker H. Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens. Open Medicine. 2010;5(2): 198-202. https://doi.org/10.2478/s11536-009-0140-4.
• Patıroğlu T, Erdoğ Şahin N, Ünal E, Kendirci M, Karakükcü M, Özdemir MA. Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels. Turk J Haematol. 2018 Mar 1;35(1):85-86. doi: 10.4274/tjh.2017.0320.
• Karacan Y, Yıldız H, Evrensel T, Haznedaroglu IC. The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy. Support Care Cancer. 2023 Jun 8;31(7):385. doi: 10.1007/s00520-023-07856-7.
• Akkoc N, Akcelik M, Haznedaroglu IC. In-vitro anti-fungal of medicinal plant extracts Ankaferd activity events as [in Turkish]. 34. In National Hematology Congress 2008 Oct.
• Akkoç N, Akçelik M, Haznedaroğlu IC, Göker H, Turgut M, Aksu S, Kirazlı S, Fırat HC. In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract.Turkiye Klinikleri J Med Sci. 2009;29(2):410-5.
• Ciftci S, Keskin F, Keceli Ozcan S, Erdem MA, Cankaya B, Bingöl R, Kasapoglu C. In Vitro Antifungal Activity of Ankaferd Blood Stopper Against Candida albicans. Current Therapeutic Research 2011; 72(3): 120-126. https://doi.org/10.1016/j.curtheres.2011.04.003.
• Ozel-Demiralp D, Igci N, Ayhan B, Egin Y, Haznedaroglu IC,Akar N. Prohemostatic and antithrombin activities of Ankaferd hemostat are linked to fibrinogen gamma chain and prothrombin by functional proteomic analyses. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis vol. 18,6 (2012): 604-10. doi:10.1177/1076029612436672
• Satar G, Akkoc A, Oktay A, Topal A, Inan K. Evaluation of the Hemostatic and Histopathological Effects of Ankaferd Blood Stopper in Experimental Liver Injury in Rats. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2013; 24(5): 518-524. https://doi.org/10.1097/MBC.0b013e32835e9498
• Koşmaz K, Durhan A, Süleyman M, Ünal Y, Bostanci M, Yiğit Haskaraca T, Ersak C,Şener M,Kuşabbi İA,Eser EP,Hücümenoğlu S. The effect of Ankaferd Blood Stopper on Liver Damage in Experimental Obstructive Jaundice. Turkish journal of medical sciences, 2021; 51(3): 1472-1480. https://doi.org/10.3906/sag-2007-298.